# Efficacy of Daily IV Administration of Dornase Alfa up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence at 6 Months

> **NCT06723717** · PHASE2 · RECRUITING · sponsor: **Fondation Ophtalmologique Adolphe de Rothschild** · enrollment: 304 (estimated)

## Conditions studied

- Ruptured Aneurysm of Intracranial Artery
- SAH (Subarachnoid Hemorrhage)
- Delayed Cerebral Ischemia

## Interventions

- **DRUG:** Daily infusion of dornase alfa

## Key facts

- **NCT ID:** NCT06723717
- **Lead sponsor:** Fondation Ophtalmologique Adolphe de Rothschild
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-26
- **Primary completion:** 2028-03
- **Final completion:** 2028-09
- **Target enrollment:** 304 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06723717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06723717, "Efficacy of Daily IV Administration of Dornase Alfa up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence at 6 Months". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT06723717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*